FLORIDA: Puget Technologies announced its subsidiary, Cannabis Biotech, is in talks with a research chemist to explore the development of an exclusive cannabis-based metered-dose transmucosal delivery platform. The transmucosal system is an effective means to introduce treatments across the mucous membrane and is a well-established and accepted system of administration. Cannabis Biotech sought out this eminently qualified professional in the beginning stages as it enters the multi-billion dollar medical marijuana industry with a commitment to maintaining strict protocols and quality standards.
This project is part of the company’s strategy to develop a wider variety of delivery methods directed towards a growing, diverse patient base. Cannabis Biotech’s research is focusing on the growing number of patients who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it.
According to one estimate, there are 24.8 million potential patients eligible for medical marijuana (The State of Marijuana Markets 2011). Currently 20 U.S. states and the District of Columbia have enacted laws to legalize the use of medical marijuana.
President and CEO of Puget Technologies Ron Leyland said, “We are looking forward to this eminent scientist joining our research team. This will bring us one step closer to our goal of providing patients with products developed under the most rigorous standards and protocols.”
The uptake of medicine via transmucosal systems is well received by patients. Flonase (fluticasone propionate) manufactured by GlaxoSmithKline (NYSE: GSK), Rhinocort Aqua (budesonide) by AstraZeneca (NYSE: AZN), and Nicotrol®NS (nicotine nasal spray) by Pfizer (NYSE: PFE) are popular medications which are commonly used in the U.S. The methodology is used as an anti-influenza therapy and to treat allergies, vitamin B deficiency, osteoporosis and nicotine addiction among other conditions.